Seeking to grow its pipeline, San Diego-based Santarus agreed to collaborate with Italian specialty drug firm Cosmo Technologies Ltd. to develop and commercialize two compounds targeting the colon in a deal worth up to $87 million plus royalties. (BioWorld Today) Read More
